USAQ.OQBQhslab, INC

SCHEDULE: QHSLab, Inc. - Marvin Smollar Family Trust Discloses 14.8% Stake

Sentiment:

Schedule 13D


Marvin Smollar Family Trust files Schedule 13D, reporting beneficial ownership of 2,226,280 shares of QHSLab, Inc. common stock, representing 14.8% of the outstanding shares.

Delay expectedThe filing acknowledges that applicable filing deadlines were not met, and this statement is being filed on a late basis.

Summary

  • The Marvin Smollar Family Trust (the "Trust") has filed a Schedule 13D, reporting beneficial ownership of 2,226,280 shares of QHSLab, Inc. common stock.
  • This holding represents approximately 14.8% of the total outstanding shares of QHSLab, Inc. common stock, based on 15,032,788 shares outstanding as of March 30, 2026.
  • The Trust acquired these shares through three separate transactions, with the first two tranches originally received by Marvin Smollar and later transferred to the Trust, and the third tranche received directly by the Trust.
  • The filing acknowledges that applicable filing deadlines were not met, and this statement is being filed on a late basis.
  • The Trust holds these shares for estate administration purposes and intends to distribute them according to the Trust instrument and estate administration procedures.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as having a neutral to slightly negative sentiment due to the late submission and the stated intention to distribute shares, which could increase selling pressure.

Positives

  • The Marvin Smollar Family Trust holds a significant stake of 14.8% in QHSLab, Inc., indicating substantial prior investment or involvement.
  • The shares were acquired through various transactions, including distributions from MedScience Research Group, Inc. and conversion of a promissory note, suggesting a history of business dealings related to the company.

Negatives

  • The filing is being submitted on a late basis, indicating a failure to meet previous SEC filing deadlines.
  • The Trust's stated intention is to distribute all shares, which could lead to increased selling pressure on the stock if not managed carefully.

Risks

  • The Trust intends to distribute all 2,226,280 shares of Common Stock pursuant to the terms of the Trust instrument and applicable estate administration procedures, which could lead to increased selling pressure on the stock.
  • The shares received on January 29, 2026, are subject to Rule 144 restrictions, which may impact the timing and manner of their sale.

Future Outlook

The Trust intends to distribute all 2,226,280 shares of Common Stock pursuant to the terms of the Trust instrument and applicable estate administration procedures. These shares are subject to Rule 144 restrictions.

Management Comments

  • The Trust holds shares solely for purpose of estate administration.
  • The Trust intends to distribute all 2,226,280 shares of Common Stock pursuant to the terms of the Trust instrument and applicable estate administration procedures.

Industry Context

StockSavvy.ai notes that Schedule 13D filings typically signal a significant ownership stake, often by an activist investor or a party with a strategic interest. In this case, the filing by a family trust for estate administration purposes suggests a passive holding that may eventually lead to liquidation, potentially impacting share supply.

Stakeholder Impact

  • Shareholders: Potential for increased selling pressure on the stock as the Trust distributes its shares.
  • Creditors: No direct impact mentioned.
  • Employees: No direct impact mentioned.
  • Suppliers: No direct impact mentioned.
  • Customers: No direct impact mentioned.

Next Steps

  • Distribution of all 2,226,280 shares of Common Stock by the Trust according to its instrument and estate administration procedures.

Key Dates

DateDescription
2019-12-27Date of original issuance of the 10% convertible promissory note.
2021-03-15Date of Convertible Note Assignment Agreement and direction for conversion of the Note.
2021-06-29Date of issuance of 584,079 shares of Common Stock as a pro-rata distribution from MedScience Research Group, Inc.
2021-09-28Date of issuance of 181,313 shares of Common Stock upon conversion of the promissory note.
2023-02-13Date of the Marvin Smollar Family Trust.
2025-11-27Date of death of grantor Marvin Smollar, upon which the Trust became irrevocable.
2025-12-31Date as of which principal and accrued interest on a promissory note to MedScience totaled approximately $470,529.
2026-01-29Date the Trust received 1,460,888 shares of Common Stock as a pro-rata distribution from MedScience Research Group, Inc.
2026-03-30Date as of which there were 15,032,788 shares of Common Stock outstanding.
2026-03-31Date of Issuer's Annual Report on Form 10-K filing.
2026-04-27Date of the Schedule 13D filing.
2026-01-29Date of QHSLab's Form 8-K filing reporting the issuance of shares to MedScience.

Recommendation

hold

The filing indicates a significant ownership stake but also a stated intention to distribute shares, suggesting potential future selling pressure. The late filing raises concerns about compliance. Without further information on the Trust's distribution strategy or QHSLab's operational performance, a 'hold' recommendation is prudent, allowing investors to monitor the situation.

Keywords

QHSLab, Inc., Schedule 13D, Marvin Smollar Family Trust, Beneficial Ownership, Common Stock, SEC Filing, Estate Administration, Rule 144

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.